<DOC>
	<DOCNO>NCT01759511</DOCNO>
	<brief_summary>The primary objective study evaluate long term safety tolerability simtuzumab ( GS-6624 ) participant idiopathic pulmonary fibrosis ( IPF ) previously participate Gilead clinical trial AB0024-201 .</brief_summary>
	<brief_title>Long-Term Safety Study GS-6624 Adults With Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Key Previous participation Phase 1 Gilead clinical trial Diagnosis idiopathic pulmonary fibrosis Females childbearing potential nonvasectomized male must agree use highly effective method contraception Females must discontinue nurse Comply study requirement Have adequate organ function Key History evidence clinically significant disorder , condition disease would pose risk interfere study Pregnant lactate Clinically significant heart , hepatic renal disease History cancer within 5 year screen Infection control despite antibiotic treatment History bleeding diathesis within last 6 month Day 1 Known history human immunodeficiency virus , hepatitis B C Concern 's subject compliance Other condition might put subject high risk treatment complication reduce chance obtain data require Placed lung transplant list Previous participation idiopathic pulmonary fibrosis clinical trial simtuzumab Note : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Idiopathic</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>IPF</keyword>
</DOC>